11 results on '"Kalenak JW"'
Search Results
2. The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes.
- Author
-
Christakis PG, Kalenak JW, Tsai JC, Zurakowski D, Kammer JA, Harasymowycz PJ, Mura JJ, Cantor LB, and Ahmed II
- Subjects
- Aged, Female, Follow-Up Studies, Glaucoma physiopathology, Humans, Incidence, Male, Prosthesis Design, Reoperation, Time Factors, Tonometry, Ocular, Treatment Outcome, Visual Acuity, Glaucoma surgery, Glaucoma Drainage Implants, Intraocular Pressure physiology, Postoperative Complications epidemiology, Trabeculectomy methods
- Abstract
Purpose: To compare 2 frequently used aqueous shunts for the treatment of glaucoma., Design: International, multicenter, randomized trial., Participants: Patients aged 18 years or older with uncontrolled glaucoma despite maximum tolerated medical therapy, many of whom had failed or were at high risk of failing trabeculectomy., Methods: Eligible patients were randomized to receive an Ahmed-FP7 valve implant (New World Medical, Inc, Rancho Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc, Santa Ana, CA) using a standardized surgical technique., Main Outcome Measures: The primary outcome was failure, defined as intraocular pressure (IOP) outside the target range (5-18 mmHg) or reduced <20% from baseline for 2 consecutive visits after 3 months, severe vision loss, or de novo glaucoma surgery. Secondary outcomes measures included IOP, medication use, visual acuity, complications, and interventions., Results: A total of 238 patients were randomized; 124 received the Ahmed-FP7 implant, and 114 received the Baerveldt-350 implant. Baseline characteristics were similar between groups. Mean preoperative IOP was 31.4±10.8 mmHg on 3.1±1.0 glaucoma medications. At 5 years, the cumulative failure rate was 53% in the Ahmed group and 40% in the Baerveldt group (P = 0.04). The main reason for failure in both groups was high IOP, and the cumulative de novo glaucoma reoperation rate was 18% in the Ahmed group and 11% in the Baerveldt group (P = 0.22). Hypotony resulted in failure in 5 patients (4%) in the Baerveldt group compared with none in the Ahmed group (P = 0.02). Mean IOP was 16.6±5.9 mmHg in the Ahmed group (47% reduction) and 13.6±5.0 mmHg in the Baerveldt group (57% reduction, P = 0.001). Mean medication use was 1.8±1.5 mmHg in the Ahmed group (44% reduction) and 1.2±1.3 mmHg in the Baerveldt group (61% reduction, P = 0.03). The 2 groups had similar complication rates (Ahmed 63%, Baerveldt 69%) and intervention rates (Ahmed 41%, Baerveldt 41%). Most complications were transient, and most interventions were slit-lamp procedures., Conclusions: Both implants were effective in reducing IOP and the need for glaucoma medications. The Baerveldt group had a lower failure rate and a lower IOP on fewer medications than the Ahmed group, but had a small risk of hypotony that was not seen in the Ahmed group., (Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
3. The Ahmed versus Baerveldt study: three-year treatment outcomes.
- Author
-
Christakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, and Ahmed II
- Subjects
- Aged, Antihypertensive Agents therapeutic use, Female, Glaucoma diagnosis, Glaucoma physiopathology, Humans, Intraocular Pressure physiology, Male, Postoperative Complications, Recurrence, Trabeculectomy, Treatment Outcome, Visual Acuity physiology, Glaucoma surgery, Glaucoma Drainage Implants, Prosthesis Implantation
- Abstract
Objective: To compare 2 commonly used aqueous drainage devices for the treatment of refractory glaucoma., Design: International, multicenter, randomized trial., Participants: Patients aged 18 years or older with uncontrolled or high-risk glaucoma refractory to maximum medical therapy, many of whom had failed trabeculoplasty and trabeculectomy., Methods: Eligible patients were randomized to an Ahmed-FP7 valve implant (New World Medical, Inc., Rancho Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc., Santa Ana, CA) using a standardized surgical technique., Main Outcome Measures: The primary outcome was failure, defined as intraocular pressure (IOP) outside of the target range (5-18 mmHg, with ≥20% reduction from baseline) for 2 consecutive visits after 3 months, vision-threatening complications, de novo glaucoma procedures, or loss of light perception. Secondary outcome measures include IOP, medication use, visual acuity, complications, and interventions., Results: A total of 238 patients were enrolled and randomized; 124 received the Ahmed implant and 114 received the Baerveldt implant. Baseline characteristics were similar in both groups. Half the study group had secondary glaucoma, and 37% had previously failed trabeculectomy. The mean preoperative IOP was 31.4±10.8 mmHg on 3.1±1.0 glaucoma medications. Median baseline Snellen visual acuity was 20/100. At 3 years, the cumulative probability of failure was 51% in the Ahmed group and 34% in the Baerveldt group (P = 0.03). Mean IOP was 15.7±4.8 mmHg in the Ahmed group (49% reduction) and 14.4±5.1 mmHg in the Baerveldt group (55% reduction; P = 0.09). Mean number of glaucoma medications was 1.8±1.4 in the Ahmed group (42% reduction) and 1.1±1.3 in the Baerveldt group (65% reduction; P = 0.002). There was a moderate but similar decrease in visual acuity in both groups (P< 0.001). The 2 groups had similar complication rates (52% Ahmed, 62% Baerveldt; P = 0.12); however, the Baerveldt group had a higher rate of hypotony-related vision-threatening complications (0% Ahmed, 6% Baerveldt; P = 0.005). More interventions were required in the Baerveldt group, although the difference did not reach statistical significance (38% Ahmed, 50% Baerveldt; P = 0.07). Most complications were transient, and most interventions were slit-lamp procedures., Conclusions: Both devices were effective in reducing IOP and glaucoma medications. The Baerveldt group had a lower failure rate and required fewer medications than the Ahmed group after 3 years, but it experienced more hypotony-related vision-threatening complications., (Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
4. The Ahmed Versus Baerveldt study: design, baseline patient characteristics, and intraoperative complications.
- Author
-
Christakis PG, Tsai JC, Zurakowski D, Kalenak JW, Cantor LB, and Ahmed II
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antihypertensive Agents administration & dosage, Female, Follow-Up Studies, Glaucoma physiopathology, Humans, Intraocular Pressure physiology, Male, Middle Aged, Prospective Studies, Prosthesis Implantation, Visual Acuity physiology, Young Adult, Glaucoma surgery, Glaucoma Drainage Implants, Intraoperative Complications, Research Design
- Abstract
Objective: To report the design, baseline patient characteristics, and intraoperative complications of the Ahmed Versus Baerveldt (AVB) Study., Design: Multicenter, randomized, clinical trial., Participants: Patients were recruited from 7 international clinical sites and treated by 10 surgeons between 2005 and 2009. Inclusion criteria required that patients be at least 18 years of age and have uncontrolled glaucoma refractory to medicinal, laser, and surgical therapy., Methods: Eligible patients were randomized to undergo implantation of an Ahmed-FP7 valve (New World Medical, Inc., Rancho Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc., Santa Ana, CA) using standardized surgical technique, to be followed for 5 years., Main Outcome Measures: The primary outcome measure was failure, defined as intraocular pressure (IOP) out of target range (5-18 mmHg with ≥ 20% reduction from baseline) for 2 consecutive visits after 3 months, vision-threatening complications, additional glaucoma procedures, or loss of light perception. Secondary outcome measures included IOP, medication use, visual acuity, complications, and interventions., Results: A total of 238 patients were enrolled in the study; 124 received the Ahmed-FP7 valve implant and 114 received the Baerveldt-350 implant. The 2 treatment groups did not differ in any baseline characteristics with the exception of sex. The mean age of the study group was 66 ± 16 years, and 55% were women, with a greater proportion in the Baerveldt group (P=0.01). The mean baseline IOP of the study group was 31.4 ± 10.8 on a mean of 3.1 ± 1.0 glaucoma medications. The median Snellen visual acuity was 20/100, mean number of previous laser therapies was 0.9 ± 1.1, and mean number of previous surgeries was 1.7 ± 1.2. Five (4%) patients in the Ahmed group and 4 (4%) patients in the Baerveldt group experienced significant intraoperative complications., Conclusions: Aqueous drainage devices are being increasingly used for glaucoma refractory to conventional treatment, and the AVB Study compares the 2 most commonly implanted devices. The 2 groups had similar baseline characteristics, and there were a similar number of intraoperative complications for both devices., Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references., (Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
5. The Ahmed Versus Baerveldt study: one-year treatment outcomes.
- Author
-
Christakis PG, Kalenak JW, Zurakowski D, Tsai JC, Kammer JA, Harasymowycz PJ, and Ahmed II
- Subjects
- Aged, Antihypertensive Agents administration & dosage, Female, Follow-Up Studies, Glaucoma physiopathology, Humans, Intraocular Pressure physiology, Male, Postoperative Complications, Prospective Studies, Prosthesis Implantation, Treatment Outcome, Visual Acuity physiology, Glaucoma surgery, Glaucoma Drainage Implants, Intraoperative Complications, Research Design
- Abstract
Objective: To report the 1-year treatment outcomes of the Ahmed Versus Baerveldt (AVB) Study., Design: Multicenter randomized clinical trial., Participants: A total of 238 patients were enrolled in the study, including 124 in the Ahmed group and 114 in the Baerveldt group., Methods: Patients aged 18 years or older with uncontrolled glaucoma refractory to medicinal, laser, and surgical therapy were randomized to undergo implantation of an Ahmed-FP7 valve (New World Medical, Inc., Rancho Cucamonga, CA) or a Baerveldt-350 implant (Abbott Medical Optics, Inc., Santa Ana, CA), to be followed for 5 years., Main Outcome Measures: The primary outcome measure was failure, defined as intraocular pressure (IOP) out of target range (5-18 mmHg with ≥ 20% reduction from baseline) for 2 consecutive visits after 3 months, vision-threatening complications, additional glaucoma procedures, or loss of light perception. Secondary outcome measures included IOP, medication use, visual acuity, complications, and interventions., Results: There were no significant differences in baseline ocular or demographic characteristics between the study groups with the exception of sex. Preoperatively, the study group had a mean IOP of 31.4 ± 10.8 mmHg on a mean of 3.1 ± 1.0 glaucoma medications with a median Snellen acuity of 20/100. The cumulative probability of failure a 1-year was 43% in the Ahmed group and 28% in the Baerveldt group (P = 0.02). The mean IOP at 1 year was 16.5 ± 5.3 mmHg in the Ahmed group and 13.6 ± 4.8 mmHg in the Baerveldt group (P < 0.001). The mean number of glaucoma medications required was 1.6 ± 1.3 in the Ahmed group and 1.2 ± 1.3 in the Baerveldt group (P = 0.03). Visual acuity was similar in both groups at all visits in the first year (P = 0.66). In the first year after surgery, there were a similar number of patients who experienced postoperative complications in the 2 groups (45% Ahmed, 54% Baerveldt, P = 0.19), but a greater number of patients in the Baerveldt group required interventions (26% Ahmed vs. 42% Baerveldt, P = 0.009)., Conclusions: The Baerveldt-350 group had a higher success rate than the Ahmed-FP7 group after 1 year of follow-up, but required a greater number of interventions., Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references., (Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
6. Retinal complications after aqueous shunt surgical procedures for glaucoma.
- Author
-
Law SK, Kalenak JW, Connor TB Jr, Pulido JS, Han DP, and Mieler WF
- Subjects
- Adult, Aged, Aged, 80 and over, Drainage, Female, Humans, Male, Middle Aged, Molteno Implants adverse effects, Retrospective Studies, Risk Factors, Visual Acuity, Aqueous Humor metabolism, Glaucoma surgery, Postoperative Complications etiology, Prostheses and Implants adverse effects, Retinal Diseases etiology
- Abstract
Objectives: To assess retinal complications and to identify risk factors for retinal complications following aqueous shunt procedures., Materials and Methods: Records of 38 consecutive aqueous shunt procedures that were performed on 36 patients at the Eye Institute of the Medical College of Wisconsin, Milwaukee, from June 1993 to March 1995 (minimum follow-up, 6 months) were reviewed. The mean +/- SD follow-up was 11.4 +/- 5.2 months (median, 10.5 months)., Results: Twelve patients (32%) had the following retinal complications: 4 serous choroidal effusions (10%) that required drainage, 3 suprachoroidal hemorrhages (8%), 2 vitreous hemorrhages (5%), 1 rhegmatogenous retinal detachment (3%), 1 endophthalmitis (3%), and 1 scleral buckling extrusion (3%). Surgical procedures for retinal complications were required in 8 (67%) of these 12 patients. Visual acuity decreased 2 lines or more in 9 (75%) of these 12 patients. The median onset of a postoperative retinal complication was 12.5 days, with 10 patients (83%) experiencing complications within 35 days. Serous choroidal effusions developed in 10 other patients (26%), and these effusions resolved spontaneously. Visual acuity decreased 2 lines or more in 2 (20%) of these additional 10 patients. Patients who experienced serious retinal complications were significantly older, had a higher rate of hypertension, and postoperative ocular hypotony. Serious retinal complications were distributed evenly among patients with Krupin valves with discs and Molteno and Baerveldt devices. Experience with the Ahmed glaucoma valve implant was limited., Conclusion: Aqueous shunt procedures may be associated with significant retinal complications and subsequent visual loss.
- Published
- 1996
- Full Text
- View/download PDF
7. Linkage of autosomal dominant iris hypoplasia to the region of the Rieger syndrome locus (4q25).
- Author
-
Héon E, Sheth BP, Kalenak JW, Sunden SL, Streb LM, Taylor CM, Alward WL, Sheffield VC, and Stone EM
- Subjects
- Female, Genes, Dominant, Genetic Markers, Humans, Male, Pedigree, Syndrome, Chromosomes, Human, Pair 4 genetics, Genetic Linkage, Glaucoma genetics, Iris abnormalities
- Abstract
Iris hypoplasia is an autosomal dominant disorder which is frequently associated with glaucoma. This glaucoma is usually resistant to medical therapy and can lead to blindness. A large family of Scandinavian descent with a five generation history of iris hypoplasia was studied. Fifteen individuals were found to have iris hypoplasia, nine of whom had associated glaucoma. In an attempt to identify the chromosomal location of the disease-causing gene, this family was genotyped with short tandem repeat polymorphisms (STRPs) known to map to loci previously associated with glaucoma. The juvenile glaucoma locus at 1q25 and a congenital glaucoma locus on 6p were both statistically excluded. However, significant linkage was demonstrated at the Rieger syndrome locus at 4q25. The highest observed LOD score was 3.70 (theta = 0) and was obtained with marker D4S1616. Three recombination events were observed in affected individuals that together demonstrate that the disease-causing gene lies between markers ACT3E03 and D4S1611, an interval of approximately 7 cM. These results suggest that autosomal dominant iris hypoplasia and Rieger syndrome are allelic.
- Published
- 1995
- Full Text
- View/download PDF
8. Compression of the intracranial optic nerve mimicking unilateral normal-pressure glaucoma.
- Author
-
Kalenak JW, Kosmorsky GS, and Hassenbusch SJ
- Subjects
- Aged, Fundus Oculi, Humans, Intraocular Pressure, Magnetic Resonance Imaging, Male, Meningeal Neoplasms complications, Meningioma complications, Nerve Compression Syndromes etiology, Optic Disk pathology, Optic Nerve Diseases etiology, Visual Acuity, Visual Fields, Glaucoma diagnosis, Nerve Compression Syndromes diagnosis, Optic Nerve Diseases diagnosis
- Abstract
A 66-year-old man developed progressive visual field loss in the inferior arcuate region of the right eye with normal central visual acuity. Intraocular pressures were normal on all but one occasion. The right optic disk showed extensive glaucomalike cupping; the left optic disk was normal. Magnetic resonance imaging revealed a tumor of the right medial sphenoid wing impinging upon the intracranial portion of the right optic nerve. It was resected via a frontotemporal craniotomy. Histopathologic examination revealed a meningothelial meningioma. The visual field and optic disk cupping remained unchanged postoperatively. To our knowledge, this is the first report in which both glaucomalike cupping and visual field loss occurred as the result of a compressive lesion of the anterior visual pathway.
- Published
- 1992
9. Transscleral neodymium: YAG laser cyclocoagulation for uncontrolled glaucoma.
- Author
-
Kalenak JW, Parkinson JM, Kass MA, and Kolker AE
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Male, Middle Aged, Postoperative Care, Prognosis, Visual Acuity, Glaucoma surgery, Light Coagulation
- Abstract
To determine the efficacy and safety of the procedure, we reviewed the records of 25 eyes of 25 patients who had received noncontact transscleral Nd:YAG laser cyclocoagulation for a variety of uncontrolled glaucomas. Thirteen to 35 pulses (mean, 22.7 pulses) had been placed 1 mm to 2 mm behind the limbus with an energy per pulse of 3.4 J to 8.2 J (mean 4.5 J). Follow-up ranged from 6 months to 23 months, with the exception of one eye, which had to be enucleated. Nine of the 25 eyes (36%) required one or two repeat treatments. Twelve (48%) had intraocular pressures at last follow-up of less than 21 mm Hg but greater than 4 mm Hg. Ten eyes (40%) developed moderate to severe pain transiently, and 10 (40%) developed substantial, but transient, inflammation. Transscleral Nd:YAG laser cyclocoagulation appears to be relatively effective and well tolerated.
- Published
- 1990
10. Glaucomalike disks without increased intraocular pressure or visual field loss.
- Author
-
Kalenak JW
- Subjects
- Diagnosis, Differential, Humans, Models, Biological, Photography, Glaucoma diagnosis, Intraocular Pressure, Visual Fields
- Published
- 1990
- Full Text
- View/download PDF
11. Presumed Sudden Leakage of a Pilocarpine Ocusert and Rhegmatogenous Retinal Detachment
- Author
-
Kalenak Jw and Zakov Zn
- Subjects
Ophthalmology ,medicine.medical_specialty ,Pilocarpine ,business.industry ,medicine ,Retinal detachment ,Glaucoma ,medicine.disease ,business ,medicine.drug ,Leakage (electronics) - Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.